Complement as a target in COVID-19?

Antonio M Risitano; Dimitrios C Mastellos; Markus Huber-Lang; Despina Yancopoulou; Cecilia Garlanda; Fabio Ciceri; John D Lambris

doi:10.1038/s41577-020-0320-7

Complement as a target in COVID-19?

Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23.

Authors

Antonio M Risitano¹, Dimitrios C Mastellos², Markus Huber-Lang³, Despina Yancopoulou⁴, Cecilia Garlanda^{5

6}, Fabio Ciceri⁷, John D Lambris⁸

Affiliations

¹ Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
² National Center for Scientific Research 'Demokritos', Aghia Paraskevi, Athens, Greece.
³ Institute of Experimental Trauma-Immunology, University Hospital of Ulm, Ulm, Germany.
⁴ Amyndas Pharmaceuticals, Glyfada, Greece.
⁵ Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
⁶ Humanitas University, Pieve Emanuele, Milan, Italy.
⁷ IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy. ciceri.fabio@hsr.it.
⁸ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. lambris@pennmedicine.upenn.edu.

Abstract

There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.

MeSH terms

Betacoronavirus / immunology
COVID-19
COVID-19 Drug Treatment
Complement Activation* / drug effects
Complement Inactivating Agents / therapeutic use
Complement System Proteins / immunology*
Coronavirus Infections / drug therapy
Coronavirus Infections / immunology*
Coronavirus Infections / therapy
Drug Delivery Systems
Humans
Immunotherapy
Pandemics
Pneumonia, Viral / immunology*
Pneumonia, Viral / therapy
Respiratory Distress Syndrome / immunology
Respiratory Distress Syndrome / therapy
Respiratory Distress Syndrome / virology
SARS-CoV-2

Substances

Complement Inactivating Agents
Complement System Proteins